Thermo Fisher Scientific Inc. $TMO Shares Bought by Groupama Asset Managment

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Groupama Asset Managment grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 14.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 145,799 shares of the medical research company's stock after buying an additional 18,919 shares during the quarter. Groupama Asset Managment's holdings in Thermo Fisher Scientific were worth $72,923,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in TMO. Van Lanschot Kempen Investment Management N.V. raised its position in shares of Thermo Fisher Scientific by 3.7% in the first quarter. Van Lanschot Kempen Investment Management N.V. now owns 321,514 shares of the medical research company's stock valued at $159,985,000 after buying an additional 11,539 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S grew its holdings in shares of Thermo Fisher Scientific by 3.6% in the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 64,888 shares of the medical research company's stock valued at $32,288,000 after purchasing an additional 2,272 shares during the period. Two Star Manager LLC grew its stake in shares of Thermo Fisher Scientific by 9.6% in the 1st quarter. Two Star Manager LLC now owns 21,698 shares of the medical research company's stock valued at $10,797,000 after buying an additional 1,905 shares during the period. Legacy Financial Advisors Inc. raised its position in Thermo Fisher Scientific by 6.0% in the first quarter. Legacy Financial Advisors Inc. now owns 2,255 shares of the medical research company's stock valued at $1,122,000 after purchasing an additional 127 shares during the period. Finally, Texas Capital Bank Wealth Management Services Inc raised its holdings in Thermo Fisher Scientific by 181.6% in the 1st quarter. Texas Capital Bank Wealth Management Services Inc now owns 2,267 shares of the medical research company's stock valued at $1,128,000 after buying an additional 1,462 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total transaction of $4,518,200.00. Following the sale, the chief executive officer owned 115,174 shares of the company's stock, valued at approximately $52,037,916.68. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,896 shares of company stock worth $8,593,838. Corporate insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of research analyst reports. Robert W. Baird boosted their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Raymond James Financial reiterated an "outperform" rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. HSBC reiterated a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. William Blair began coverage on Thermo Fisher Scientific in a research report on Monday. They set an "outperform" rating for the company. Finally, Wall Street Zen cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, August 10th. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and a consensus target price of $593.00.

Thermo Fisher Scientific Stock Performance

TMO traded up $16.4780 on Friday, hitting $500.2380. 1,778,365 shares of the company traded hands, compared to its average volume of 2,484,360. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $627.88. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company has a 50 day moving average of $441.06 and a 200-day moving average of $458.02. The stock has a market capitalization of $188.89 billion, a PE ratio of 28.93, a PEG ratio of 2.64 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the prior year, the firm earned $5.37 EPS. Thermo Fisher Scientific's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.